Pfizer’s late-stage coronavirus vaccine trial is near complete enrollment with 42,000 volunteers
Pfizer’s late-stage coronavirus vaccine trial has enrolled more than 42,000 volunteers, the company announced Tuesday when it released a mixed third-quarter earnings report.
It said nearly 36,000 of the volunteers have already received the second of its two-dose Covid-19 vaccine. Pfizer has as been working alongside German drugmaker BioNTech on the experimental vaccine. It contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.
The phase three trials are a critical last step needed to get the vaccines cleared for distribution. Three other U.S.-backed candidates are in phase three: Moderna, AstraZeneca and Johnson & Johnson. Pfizer expects to apply for an emergency use authorization with the Food and Drug Administration next month.
Pfizer not yet ready to release COVID-19 vaccine data
Pfizer said in a presentation that the independent monitor which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet. Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month.
Pfizer shares fell 1% to $37.49.
Pfizer CEO: may be a week between conclusive vaccine data, public notification
Pfizer Inc's PFE.N Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE 22UAy.F works, it could be a week before it lets the public know, making it unlikely it will release data before the Nov. 3 presidential election.
Reference: Reuters, CNBC
Thai
Eng